Gilead’s Veklury should be effective against COVID-19 variants

Gilead Sciences has released a statement regarding the efficacy of its antiviral treatment Veklury (remdesivir), maintaining confidence in the its continued benefit against new COVID-19 variants. The new COVID-19 variants were discovered in the UK and South Africa, respectively. The UK variant, known as B117, was identified in the UK in early December, and was discovered to be much more transmissible than the original strain. The South African variant, known as B1351 or 501.V2, carries a number of mutations and is also thought to be more contagious. “We have completed genetic analysis of publicly available sequences for the UK and South African variants of SARS-CoV-2 and we believe remdesivir will continue to be effective against these variants,” said Gilead. “The mutations identified in these new variants have not significantly altered the part of the virus that remdesivir targets or have any association with known mutations conferring reduced susceptibility of coronaviruses ...

• Source: drugdu
• 205
• January 27, 2021